? Cancer Therapeutics Program (CTP) The overall goal of this 25-year-old Program at the Abramson Cancer Center (ACC) is to use mechanistic insights emerging from our basic science labs and CCSG Programs to improve cancer therapy for patients with advanced solid tumors. CTP accomplishes this goal through three Specific Aims: 1) Translate mechanistic biologic insights into Phase I trials; 2) Use data from Phase I trials to perform Phase II and Phase III trials to change clinical practice; and 3) Discover and develop innovative biomarkers that enhance safety and efficacy of cancer therapies. This Program is co-led by Program Leaders (PLs) Drs. Ravi Amaravadi and Naomi Haas, both appointed in 2013. Drs. Amaravadi and Haas are NCI-funded researchers who bring highly complementary scientific visions and a notable depth of experience as accomplished translational researchers. CTP encompasses a full range of basic, translational, and clinical research. CTP works closely with leaders of the ACC Community Outreach and Engagement (COE) to understand the cancer burden in the ACC catchment area and ensure that CTP research addresses the major unmet needs in our catchment area. CTP members work on improving cancer therapies for patients with advanced, lethal and often highly symptomatic solid tumors, including lung, prostate and pancreas cancer, as well as melanoma and others. During the current funding period, the PLs aggressively recruited new junior and senior investigators to CTP, reorganized the Program into disease-focused groups, and promoted intra-Programmatic interactions through carefully selected and relevant scientific themes including autophagy, cancer cell metabolism, targeted therapies, and immunotherapy. These efforts resulted in new multi-investigator grants, including NCI Program Project grants and SPORES that include CTP members, new leadership positions in National Groups, and an increase in collaborative publications. Interventional trial accruals were more than 640 per year on average (in CTP alone), representing an increase compared to the prior funding period; 59% of interventional accruals were on investigator-initiated trials. Major accomplishments include validating autophagy as a cancer target, translating basic findings in DNA damage to new therapies in ovarian and pancreatic cancer, determining the pharmacodynamics of PD-1 therapy in patients with earlier stage melanoma, testing novel immunotherapies such as monalizumab, CD40 mAb, and CAR T cells in patients with solid tumors, and advancing circulating DNA as a biomarker of response in lung cancer. The 31 CTP full members and 28 CTP associate members represent six departments from two schools at Penn. CTP members have $14.7M in annual cancer-related research grant funding (direct costs), of which $3.1M is NCI-funded and $4.5M is peer-reviewed. This represents an increase in total funding of $8M (120% increase) since 2015. Our Program has 16 R01- equivalents. There are 540 cancer-related publications from the Program since 2015. Of these, 19% are intra- Programmatic, 38% resulted from inter-Programmatic collaborations, and 74% are multi-institutional.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:

Showing the most recent 10 out of 1047 publications